$SWTX short stroke champion strong revenue NASDAQ:SWTX strong revenue seeing positive reaction. Bouncing off yesterday's high.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.48 USD
−258.13 M USD
191.59 M USD
70.37 M
About SpringWorks Therapeutics, Inc.
Sector
Industry
CEO
Saqib Islam
Website
Headquarters
Stamford
Founded
2017
FIGI
BBG00Q011TW9
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
SWTX (SpringWorks Therapeutics) - Bullish end to QuarterSPRINGWORKS THERAPEUTICS INC.
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in cl
SpringWorks $50 BullDouble dip, butterflies and new support suggest this could move towards $50. This is also supported by bullish broker sentiment.
Springworks Therapeutics, on Breakout alert $swtxMassive breakout potential setting up.
Short interest 7%
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BG
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of SWTX is 37.92 USD — it has increased by 2.32% in the past 24 hours. Watch SpringWorks Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange SpringWorks Therapeutics, Inc. stocks are traded under the ticker SWTX.
SWTX stock has risen by 7.56% compared to the previous week, the month change is a −21.86% fall, over the last year SpringWorks Therapeutics, Inc. has showed a −13.11% decrease.
We've gathered analysts' opinions on SpringWorks Therapeutics, Inc. future price: according to them, SWTX price has a max estimate of 84.00 USD and a min estimate of 63.00 USD. Watch SWTX chart and read a more detailed SpringWorks Therapeutics, Inc. stock forecast: see what analysts think of SpringWorks Therapeutics, Inc. and suggest that you do with its stocks.
SWTX reached its all-time high on Feb 9, 2021 with the price of 96.48 USD, and its all-time low was 13.60 USD and was reached on May 27, 2022. View more price dynamics on SWTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SWTX stock is 4.53% volatile and has beta coefficient of 1.06. Track SpringWorks Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is SpringWorks Therapeutics, Inc. there?
Today SpringWorks Therapeutics, Inc. has the market capitalization of 2.83 B, it has increased by 1.27% over the last week.
Yes, you can track SpringWorks Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
SpringWorks Therapeutics, Inc. is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
SWTX earnings for the last quarter are −1.04 USD per share, whereas the estimation was −0.71 USD resulting in a −47.07% surprise. The estimated earnings for the next quarter are −0.76 USD per share. See more details about SpringWorks Therapeutics, Inc. earnings.
SpringWorks Therapeutics, Inc. revenue for the last quarter amounts to 61.55 M USD, despite the estimated figure of 57.16 M USD. In the next quarter, revenue is expected to reach 65.71 M USD.
SWTX net income for the last quarter is −77.30 M USD, while the quarter before that showed −53.53 M USD of net income which accounts for −44.40% change. Track more SpringWorks Therapeutics, Inc. financial stats to get the full picture.
No, SWTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 18, 2025, the company has 368 employees. See our rating of the largest employees — is SpringWorks Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SpringWorks Therapeutics, Inc. EBITDA is −274.66 M USD, and current EBITDA margin is −143.36%. See more stats in SpringWorks Therapeutics, Inc. financial statements.
Like other stocks, SWTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SpringWorks Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SpringWorks Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SpringWorks Therapeutics, Inc. stock shows the sell signal. See more of SpringWorks Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.